They didn't as they needed these PK trials completed prior to using it in a Phase 2 trial. They used their ECS BioAbsorb soft gel capsule for which they did Phase 1 trials late 2022 and it outperformed both Epidiolex (20%) and CBD isolate (400%) with respect to bioavailability (refer their announcement 22 November 2022).
I think the key factor for Aquaphase is its solubility and ability to use it across all lipophilic compounds which makes it applicable for a variety of drugs rather than just CBD. It is seemingly a more simple and inexpensive process than typical encapsulation based on this announcement which sounds positive.
- Forums
- ASX - By Stock
- BOD
- Ann: Completion of Pivotal Aqua Phase PK Studies
Ann: Completion of Pivotal Aqua Phase PK Studies, page-11
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOD (ASX) to my watchlist
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BOD (ASX) Chart |
Day chart unavailable
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online